LCS
SPRY icon

Levin Capital Strategies’s ARS Pharmaceuticals SPRY Stock Holding History

Levin Capital Strategies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.44M Sell
552,561
-194,945
-26% -$1.87M 0.34% 76
2025
Q4 		$8.71M Sell
747,506
-16,788
-2% -$163K 0.75% 41
2025
Q3 		$7.68M Buy
764,294
+475,147
+164% +$6.82M 0.69% 44
2025
Q2 		$5.05M Sell
289,147
-875,454
-75% -$12.6M 0.49% 49
2025
Q1 		$14.7M Buy
1,164,601
+696,974
+149% +$8.39M 1.55% 23
2024
Q4 		$4.93M Buy
467,627
+198,201
+74% +$2.78M 0.47% 51
2024
Q3 		$3.91M Buy
269,426
+186,176
+224% +$2.21M 0.37% 53
2024
Q2 		$708K Buy
83,250
+28,000
+51% +$248K 0.07% 100
2024
Q1 		$565K Buy
55,250
+3,000
+6% +$22.4K 0.06% 123
2023
Q4 		$286K Sell
52,250
-11,750
-18% -$51.5K 0.03% 192
2023
Q3 		$242K Sell
64,000
-105,074
-62% -$690K 0.03% 212
2023
Q2 		$1.13M Buy
169,074
+28,723
+20% +$192K 0.13% 86
2023
Q1 		$914K Buy
140,351
+101,341
+260% +$779K 0.11% 87
2022
Q4 		$333K Buy
+39,010
New +$253K 0.04% 153

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Levin Capital Strategies's SPRY Position: Q1 2026 in Review

Levin Capital Strategies reduced its ARS Pharmaceuticals (SPRY) stake by 26% in Q1 2026, selling an estimated $1.87M and leaving 552,561 shares worth $4.44M. The position accounts for 0.34% of the portfolio, ranked #76.

Levin Capital Strategies first reported a position in SPRY in Q4 2022 and has held it in 14 quarters since. The position peaked at $14.7M in Q1 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Levin Capital Strategies held 552,561 shares of ARS Pharmaceuticals worth $4.44M as of Q1 2026.
  • Levin Capital Strategies sold 194,945 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.87M.
  • ARS Pharmaceuticals made up 0.34% of Levin Capital Strategies's portfolio in Q1 2026, its #76 holding.
  • Levin Capital Strategies first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Levin Capital Strategies's ARS Pharmaceuticals position peaked at $14.7M in Q1 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Levin Capital Strategies's 13F filing for Q1 2026, filed 13 May 2026.